Cryofocus Medtech (Shanghai) Co., Ltd. (CRYOFOCUS-B) has released its Monthly Return for Equity Issuer for the period ended 30 June 2026, confirming a stable capital structure and full compliance with Hong Kong Stock Exchange (HKEX) public-float rules.

The company’s registered share capital remained at 244.71 million shares with a par value of RMB 1 each. Of this total, 149.03 million are H-shares listed on HKEX, while 95.67 million are unlisted domestic shares. No changes occurred in either category during the month, leaving total issued shares unchanged at 244.71 million. The company holds no treasury shares.

CRYOFOCUS-B affirmed that its H-share public float continued to meet HKEX’s minimum threshold of 25% of the relevant share class, ensuring sufficient market liquidity.

The filing also noted that throughout June 2026 the company undertook no share repurchases, issuances, option grants, warrant exercises, or convertible events, indicating no shareholder dilution or capital structure adjustments.

The report was submitted on 2 July 2026 and signed by Director Mr Zhu Jun.